- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
CDRH names permanent director
Food and Drug Administration Commissioner Dr. Jane Henney this month appointed Dr. David Feigal director of the agency’s Center for Devices and Radiological Health. Feigal replaces former director Dr. Bruce Burlington, who left the FDA in March, and
Food and Drug Administration Commissioner Dr. Jane Henney this month appointed Dr. David Feigal director of the agencys Center for Devices and Radiological Health. Feigal replaces former director Dr. Bruce Burlington, who left the FDA in March, and acting director Elizabeth Jacobson (SCAN 3/3/99). Feigals new position is effective immediately.
Feigal joined the FDA in 1992, and has served as head of the Center for Drug Evaluation and Researchs division of antiviral drug products and as medical deputy director of the FDAs Center for Biologics Evaluation and Research. He was a principal investigator in studies that led the FDA to approve a drug-device combination that was one of the earliest therapies for AIDS.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
